SQZ insider filings
SQZ Biotechnologies Co — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-06-15. Screen SQZ transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for SQZ between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — SQZ Biotechnologies Co
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-06-15 | 4 | SCHEGERIN MARC — Director | Grant/award (A): 39,875 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | Jensen Klavs F. — Director | Grant/award (A): 39,875 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | Garg Pushkal — Director | Grant/award (A): 39,875 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | Elia Marc — Director | Grant/award (A): 39,875 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | Coulie Bernard — Director | Grant/award (A): 39,875 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | BOLNO PAUL — Director | Grant/award (A): 39,875 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | Srivastava Sapna — Director | Grant/award (A): 39,875 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | VINK PATRICK V.J.J. — Director | Grant/award (A): 39,875 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | SCHULMAN AMY W — Director, 10% owner | Grant/award (A): 39,875 (derivative) @ $0 | EDGAR |
| 2023-01-26 | 4 | Capasso Richard — See Remarks | Grant/award (A): 213,000 (derivative) @ $0 | EDGAR |
| 2023-01-26 | 4 | Warren Marshelle Smith — Chief Medical Officer | Grant/award (A): 261,000 (derivative) @ $0 | EDGAR |
| 2023-01-26 | 4 | First David — Chief People Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2023-01-26 | 4 | Knopf Lawrence J — General Counsel | Grant/award (A): 227,000 (derivative) @ $0 | EDGAR |
| 2023-01-26 | 4 | BERNSTEIN HOWARD PHD MD — Interim Chief Executive Office, Director | Grant/award (A): 830,000 (derivative) @ $0 | EDGAR |
| 2022-08-16 | 4 | Capasso Richard — See Remarks | Sale (S): 1,183 @ $3.33 | EDGAR |
| 2022-07-13 | 4 | Zajic Micah — Chief Financial Officer | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-07-05 | 4 | Sharei Armon — President and CEO, Director | Grant/award (A): 2,436 @ $2.70 | EDGAR |
| 2022-07-05 | 4 | Capasso Richard — See Remarks | Grant/award (A): 1,183 @ $2.70 | EDGAR |
| 2022-07-05 | 4 | Knopf Lawrence J — General Counsel | Grant/award (A): 1,484 @ $2.70 | EDGAR |
| 2022-06-16 | 4 | Garg Pushkal — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | BOLNO PAUL — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | Jensen Klavs F. — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | SCHEGERIN MARC — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | Elia Marc — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | Coulie Bernard — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | Srivastava Sapna — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | VINK PATRICK V.J.J. — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | SCHULMAN AMY W — Director, 10% owner | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-03 | 4 | Warren Marshelle Smith — Chief Medical Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2022-05-27 | 4 | Jensen Klavs F. — Director | Purchase (P): 14,326 @ $3.52 | EDGAR |
| 2022-02-15 | 4 | Zajic Micah — Chief Business Officer | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2022-02-15 | 4 | First David — Chief People Officer | Grant/award (A): 66,000 (derivative) @ $0 | EDGAR |
| 2022-02-15 | 4 | Capasso Richard — See Remarks | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2022-02-15 | 4 | Sharei Armon — President and CEO, Director | Grant/award (A): 395,000 (derivative) @ $0 | EDGAR |
| 2022-02-15 | 4 | Knopf Lawrence J — General Counsel | Grant/award (A): 97,000 (derivative) @ $0 | EDGAR |
| 2022-02-15 | 4 | BERNSTEIN HOWARD PHD MD — Chief Scientific Officer | Grant/award (A): 195,000 (derivative) @ $0 | EDGAR |
| 2022-01-13 | 4 | Sharei Armon — President and CEO, Director | Option exercise (M): 13,000 @ $1.81 · Option exercise (M): 13,000 (derivative) @ $1.81 | EDGAR |
| 2022-01-04 | 4 | Sharei Armon — President and CEO, Director | Grant/award (A): 1,686 @ $7.59 | EDGAR |
| 2022-01-04 | 4 | Knopf Lawrence J — General Counsel | Grant/award (A): 454 @ $7.59 | EDGAR |
| 2021-12-23 | 4 | SCHULMAN AMY W — Director, 10% owner | Option exercise (M): 10,091 @ $2.02 · Option exercise (M): 7,458 @ $4.59 · Option exercise (M): 6,581 @ $4.59 · Option exercise (M): 10,091 (derivative) @ $0 · Option exercise (M): 7,458 (derivative) @ $0 · Option exercise (M): 6,581 (derivative) @ $0 | EDGAR |
| 2021-12-22 | 4 | Sharei Armon — President and CEO, Director | Option exercise (M): 11,049 @ $1.81 · Option exercise (M): 11,049 (derivative) @ $0 | EDGAR |
| 2021-12-15 | 4 | SCHULMAN AMY W — Director, 10% owner | Purchase (P): 1,850 @ $10.88 · Purchase (P): 1,850 @ $10.94 | EDGAR |
| 2021-07-01 | 4 | Coulie Bernard — Director | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2021-07-01 | 4 | VINK PATRICK V.J.J. — Director | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | SCHEGERIN MARC — Director | Grant/award (A): 10,500 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | Garg Pushkal — Director | Grant/award (A): 10,500 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | Jensen Klavs F. — Director | Grant/award (A): 10,500 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | BOLNO PAUL — Director | Grant/award (A): 10,500 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | Srivastava Sapna — Director | Grant/award (A): 10,500 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | SCHULMAN AMY W — Director, 10% owner | Grant/award (A): 10,500 (derivative) @ $0 | EDGAR |
Recent 8-K events — SQZ Biotechnologies Co
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2023-12-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-10-02 | 8-K | ? 2.06 — Material Impairments 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2023-09-15 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2023-07-25 | 8-K | 8.01 — Other Events | EDGAR |
| 2023-07-07 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-07-03 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8.01 — Other Events | EDGAR |
| 2023-06-15 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
| 2023-04-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2023-01-18 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-12-06 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SQZ returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs